Tabriz University of Medical Sciences About    Newsletter    Contact Us    Create Account    Log in  
Advanced Pharmaceutical Bulletin
ISSN: 2228-5881      eISSN: 2251-7308  
Services
Export citation
EndNote
Reference Manager
BibTeX
Medlars
Refworks
Mendeley

Cite by
Google Scholar
PMC(0)


Article History
Submitted: 07 Jun 2015
Revised: 09 Oct 2015
Accepted: 12 Oct 2015
First published online: 31 Dec 2015

Article Access Statistics
Abstract Page Views: 282
PDF Downloads: 124
Full Text Views: 0

Adv Pharm Bull. 2015;5(5):649-652 doi: 10.15171/apb.2015.088
PMID:26793611        PMCID:PMC4708036

Molecular Targeting of Her-2/neu Protein Is Not Recommended as an Adjuvant Therapy in Oral Squamous Cell Carcinoma and Oral Lichen Planus

Original Research

Maryam Kouhsoltani 1, Amirala Aghbali 1, Behrooz Shokoohi 2 * , Ronak Ahmadzadeh 3

1 Dental and Periodontal Research Center and Department of Oral and Maxillofacial Pathology, Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran.
2 Hematology Oncology Research Center and Department of Pathology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.



Abstract
Purpose: Target therapy against molecular markers of EGFR family has been recently used in the treatment protocol of several diseases. However, the role of Her-2/neu in OSCC is a matter of controversy and more studies are required to clarify the role of Her-2/neu in OSCC. We aimed to investigate the role of Her-2/neu in the process of carcinogenesis in oral epithelium as ELP is a premalignant and OSCC is a malignant lesion, but RLP shows no evidence of premalignancy and malignancy.To our Knowledge, this is the first study comparing Her-2/neu expression in erosive lichen planus (ELP), reticular lichen planus (RLP), and oral squamous cell carcinoma (OSCC). Methods: 60 samples, including 20 cases of RLP, 20 cases of ELP, and 20 cases of OSCC were evaluated immunohistochemically in this study. Results: Our findings showed that there was not a significant increase in Her-2/neu expression from RLP to ELP and from ELP to OSCC. Therefore, Her-2/neu had no role in differentiating between RLP, ELP and OSCC and this protein does not contribute to the process of carcinogenesis in the oral epithelium. Conclusion: The lack of Her-2/neu overexpression indicates that molecular targeting of Her-2/neu protein is not recommended as an adjuvant therapy in OSCC and OLP.





Comments
First name  
Last name  
Email address  
Comments  
Security code



This Article
PDF

Google Scholar
Articles by Kouhsoltani M
Articles by Aghbali A
Articles by Shokoohi B
Articles by Ahmadzadeh R

PubMed
Articles by Kouhsoltani M
Articles by Aghbali A
Articles by Shokoohi B
Articles by Ahmadzadeh R

Similar articles in PubMed

Share this article!

Press Manuscript Online. Powered by MAADRAYAN